Bone Marrow Progenitor Cell Mobilization in Diabetes

NCT ID: NCT01102699

Last Updated: 2013-09-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2013-08-31

Brief Summary

Diabetes mellitus is associated with a significant reduction of circulating progenitor cells (CPCs). These include endothelial progenitor cells (EPCs), which are involved in cardiovascular homeostasis and repair. A reduction of CPCs in metabolic patients is associated with an increased risk of future adverse cardiovascular outcomes. Therefore, ways to active stimulate an increase of CPC levels in diabetes are actively pursued.

Experimental animal studies and preliminary data in humans indicate that a bone marrow defect is causally related to the low CPC level in diabetes.

Our previous data in rats indicate that diabetes reduces the bone marrow responsiveness to granulocyte colony-stimulating factor (G-CSF) in terms of progenitor cell mobilization.

In the present study, we aim at investigating bone marrow responsiveness to pharmacological mobilization of CPC in diabetic patients as compared to non-diabetic subjects.

Detailed Description

Diabetes mellitus is associated with a significant reduction of circulating progenitor cells (CPCs). CPCs are defined by the surface expression of the stem cell antigen CD34 and or CD133. These cells include endothelial progenitor cells (EPCs), which are involved in cardiovascular homeostasis and repair. EPCs are characterized by the co-expression of endothelial antigen(s), such as KDR.

A reduction of CPCs in metabolic patients is associated with an increased risk of future adverse cardiovascular outcomes, such as myocardial infarction, stroke, revascularization, etc. Therefore, ways to active stimulate an increase of CPC levels in diabetes are actively pursued. Indeed, there are several drugs that stimulate CPCs or EPCs, but it is not fully clear if they are active also in diabetic patients.

The mechanisms that account for CPC reduction in diabetes include defective bone marrow mobilization, reduced survival and increased homing outside the bloodstream. Experimental animal studies and preliminary data in humans indicate that a bone marrow defect is causally related to the low CPC level in diabetes.

Our previous data in rats indicate that diabetes reduces the bone marrow responsiveness to G-CSF in terms of c-kit+/Sca-1+ progenitor cell mobilization.

There is also some experimental evidence in type 2 diabetic rats that a specific form of autonomic neuropathy impairs bone marrow mobilization of progenitor cells.

In the present study, we aim at investigating bone marrow responsiveness to pharmacological mobilization of CPC in diabetic patients as compared to non-diabetic subjects.

Diabetic subjects and control subjects will be administered with a single dose of granulocyte colony stimulating factor (G-CSF) and progenitor cells will be quantified before and 24 hours after G-CSF administration. Progenitor cells will be analyzed by flow cytometry on the basis of the expression of CD34, CD133 and KDR.

Mean percentage variation of CPCs and EPCs will be compared in diabetic versus non diabetic patients to understand whether or not diabetes is associated with a significant defective mobilization of progenitor cells.

As a secondary aim, diabetic patients will be divided in those with and without diabetic autonomic neuropathy (DAN) to understand if DAN modulates bone marrow responsiveness to G-CSF.

Conditions

Diabetes Mellitus

Keywords

Diabetes; stem cells; bone marrow; mobilization

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Filgrastim, G-CSF

Single s.c. dose of G-CSF (300 microg)

Group Type: EXPERIMENTAL

Filgrastim, hrG-CSF

Intervention Type: DRUG

Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)

Interventions

Filgrastim, hrG-CSF

Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diabetes mellitus (for cases) or absence of diabetes (for controls);
• Age 25-65;
• Both sexes;
• Capability of providing informed consent.

Exclusion Criteria

• Age <25 or >65;
• Fertile women;
• Recent (within 2 months) acute illnesses;
• Chronic immune of infectious diseases;
• Current or remote hematological disorders;
• Leukocytosis, leukopenia or thrombocytopenia;
• Organ transplantation or immune suppression;
• Altered liver function;
• Severe renal failure (eGFR<30 mL/min/m2);
• Anomalies in lymphocytes subpopulations;
• High basal level of CD34+ cell count;
• Allergy to Filgrastim;
• Bronchial asthma or other chronic lung disorders;
• Current or remote cancer;
• Deny or impossibility to provide informed consent.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Padova

OTHER

Sponsor Role: lead

Responsible Party

Angelo Avogaro

Professor of Endocrinology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Angelo Avogaro, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Medicine, University of Padova, Medical School, Padova (Italy)

Gian Paolo Fadini, MD

Role: STUDY_DIRECTOR

Department of Medicine, University of Padova.

Locations

University Hospital, Division of Metabolic Diseases

Padua, , Italy

Countries

Italy

References

Fadini GP, Albiero M, Vigili de Kreutzenberg S, Boscaro E, Cappellari R, Marescotti M, Poncina N, Agostini C, Avogaro A. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care. 2013 Apr;36(4):943-9. doi: 10.2337/dc12-1084. Epub 2012 Oct 30.

Reference Type: DERIVED

PMID: 23111057 (View on PubMed)

Other Identifiers

GCSF-DM

Identifier Type: -

Identifier Source: org_study_id